Maharashtra FDA cancels Cipla Pune unit licences over compliance violations
Maharashtra FDA cancelled the drug-sale licences of Cipla’s Pune C&F unit after flagging misbranded Reactin Plus packaging, incomplete recall compliance, stock-record discrepancies and improper storage. Inventory valued at Rs 11.19 lakh was seized.
What happened
Cipla Pharma & Life Sciences Ltd · Maharashtra FDA cancelled Cipla’s Pune C&F unit drug-sale licences after finding misbranded Reactin Plus packaging,
Key facts
- Rs 11.19 lakh
- August 27
- Drugs and Cosmetics Act, 1940
- Drugs Rules, 1945
Why this matters
The action highlights compliance diligence risks in Indian pharma distribution, making quality-system resilience and regulatory track record central to any partnership or acquisition assessment.
What to watch
- Maharashtra FDA order details, duration of cancellation and conditions for restoration.
- Evidence of additional product recalls, expanded seizures or penalties.
- Whether inspections extend to other Cipla warehouses, plants or states.
- Availability and pharmacy-level pricing of Reactin Plus and related Cipla OTC products in Maharashtra.
- Company disclosure of financial impact, alternate-distribution arrangements or remediation timelines.
- Any CDSCO involvement or follow-on action by other state drug regulators.
- Submit a formal corrective-and-preventive-action plan and seek expedited licence reinstatement.
- Shift Maharashtra supply flows to compliant alternate C&F facilities to limit pharmacy stock-outs.
- Complete and document a full traceable recall of affected Reactin Plus lots, including retailer-level verification.
- Audit stock reconciliation, temperature/storage logs, expiry controls and packaging-release processes across Indian distribution sites.
- Increase communication with regulators, distributors and pharmacies to distinguish affected lots from unaffected Cipla products.